Cadrenal Therapeutics Inc (CVKD) USD0.001

Sell:$12.66Buy:$13.49$0.71 (5.32%)

Prices delayed by at least 15 minutes
Sell:$12.66
Buy:$13.49
Change:$0.71 (5.32%)
Prices delayed by at least 15 minutes
Sell:$12.66
Buy:$13.49
Change:$0.71 (5.32%)
Prices delayed by at least 15 minutes

Company Information

About this company

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to overcome the gaps in anticoagulation therapy. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). It also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.

Key people

Quang Pham
Chairman of the Board, Chief Executive Officer
Matthew K. Szot
Chief Financial Officer
Jeffrey Cole
Chief Operating Officer
James J. Ferguson
Chief Medical Officer
John R. Murphy
Independent Director
Glynn Wilson
Independent Director
Steven Zelenkofske
Independent Director
Click to see more

Key facts

  • EPIC
    CVKD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1276362076
  • Market cap
    $27.36m
  • Employees
    4
  • Shares in issue
    2.05m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.